RxDoctor Payments Data

Vijaya Ganta, MD

Internal Medicine · Washington, DCNPI 1851495493

Payments from drug & device makers

$900in general payments, 2019–2025

Across 40 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$281
  • Corcept Therapeutics$137
  • Novo Nordisk$130
  • Lilly USA, LLC$99
  • Amgen$45
  • Boehringer Ingelheim$41
  • plus $167 from 8 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 75th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$27,322
Medicare patients
90
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro25$7,832
JanuviaSitagliptin Phosphate14$5,540
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,020
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,684
Humalog Kwikpen U-100Insulin Lispro17$3,244
Novolog FlexpenInsulin Aspart11$2,899
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$1,918
HumalogInsulin Lispro11$1,491
LantusInsulin Glargine,hum.Rec.Anlog12$1,348
Metformin Hcl77$686
Atorvastatin Calcium52$578
Levothyroxine Sodium53$345
Amlodipine Besylate19$216
Lisinopril22$152
Methimazole12$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCHumalog$99$1,49111 claims
Sanofi-aventis U.S. LLCLantus$18$1,34812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →